

**Supplementary Table 6.** Trends in dual combination of antidiabetic agents among insulin users with type 2 diabetes mellitus from 2002 to 2010

	2002	2003	2004	2005	2006	2007	2008	2009	2010
Metformin+SU	11,499 (10.46)	12,969 (10.31)	14,745 (10.94)	18,056 (11.53)	20,077 (11.18)	21,398 (10.99)	24,229 (11.18)	27,608 (11.83)	29,689 (12.19)
Metformin+DPP-4i	-	-	-	-	-	-	66 (0.03)	1,759 (0.75)	2,560 (1.05)
Metformin+SGLT2i	-	-	-	-	-	-	-	-	-
Metformin+GLP-1 RA	-	-	-	-	-	-	-	-	2 (0)
Metformin+TZD	394 (0.36)	376 (0.30)	548 (0.41)	795 (0.51)	1,087 (0.61)	869 (0.45)	936 (0.43)	1,129 (0.48)	957 (0.39)
Metformin+Meglitinide	85 (0.08)	324 (0.26)	379 (0.28)	668 (0.43)	1,206 (0.67)	1,674 (0.86)	2,105 (0.97)	2,318 (0.99)	2,431 (1.00)
Metformin+AGI	2,150 (1.96)	2,682 (2.13)	2,955 (2.19)	3,414 (2.18)	4,031 (2.24)	4,554 (2.34)	5,725 (2.64)	6,999 (3.00)	7,747 (3.18)
SU+DPP-4i	-	-	-	-	-	-	3 (0)	50 (0.02)	55 (0.02)
SU+SGLT2i	-	-	-	-	-	-	-	-	-
SU+GLP-1 RA	-	-	-	-	-	-	-	-	1 (<0.01)
SU+TZD	800 (0.73)	1,177 (0.94)	1,241 (0.92)	1,534 (0.98)	1,797 (1.00)	1,241 (0.64)	1,551 (0.72)	1,558 (0.67)	1,172 (0.48)
SU+AGI	3,291 (2.99)	3,540 (2.81)	3,255 (2.42)	3,361 (2.15)	4,085 (2.28)	3,855 (1.98)	4,266 (1.97)	4,201 (1.80)	3,996 (1.64)
TZD+DPP-4i	-	-	-	-	-	-	2 (<0.01)	6 (<0.01)	6 (<0.01)
Meglitinide+AGI	36 (0.03)	66 (0.05)	112 (0.08)	220 (0.14)	503 (0.28)	774 (0.40)	1,043 (0.48)	1,233 (0.53)	1,105 (0.45)

Values are presented as number (%).

SU, sulfonyleurea; DPP-4i, dipeptidyl peptidase-4 inhibitor; SGLT2i, sodium glucose cotransporter 2 inhibitor; GLP-1 RA, glucagon-like peptide-1 receptor agonist; TZD, thiazolidine-dione; AGI, alpha glucosidase inhibitor.